WO2005058359A3 - Procede de neutralisation des effets de la crp en vue d'augmenter les reactions immunitaires contre le vih - Google Patents

Procede de neutralisation des effets de la crp en vue d'augmenter les reactions immunitaires contre le vih Download PDF

Info

Publication number
WO2005058359A3
WO2005058359A3 PCT/EP2004/053496 EP2004053496W WO2005058359A3 WO 2005058359 A3 WO2005058359 A3 WO 2005058359A3 EP 2004053496 W EP2004053496 W EP 2004053496W WO 2005058359 A3 WO2005058359 A3 WO 2005058359A3
Authority
WO
WIPO (PCT)
Prior art keywords
crp
hiv
immune reactions
pentameric
increasing immune
Prior art date
Application number
PCT/EP2004/053496
Other languages
English (en)
Other versions
WO2005058359A2 (fr
Inventor
Ahmed Sheriff
Birgit Vogt
Original Assignee
Theralogic Gmbh & Co Kg
Ahmed Sheriff
Birgit Vogt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theralogic Gmbh & Co Kg, Ahmed Sheriff, Birgit Vogt filed Critical Theralogic Gmbh & Co Kg
Publication of WO2005058359A2 publication Critical patent/WO2005058359A2/fr
Publication of WO2005058359A3 publication Critical patent/WO2005058359A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une composition pharmaceutique qui permet de réduire la concentration de la protéine C-réactive (CRP) pentamérique en vue de bloquer ou de neutraliser la CRP pentamérique. Cette composition pharmaceutique contient une dose thérapeutiquement efficace d'un anticorps qui possède un site anticorps pour la protéine CRP ou un fragment d'anticorps ou un dérivé qui possède un site anticorps pour la protéine CRP pentamérique, ainsi qu'un excipient acceptable sur le plan pharmaceutique.
PCT/EP2004/053496 2003-12-15 2004-12-15 Procede de neutralisation des effets de la crp en vue d'augmenter les reactions immunitaires contre le vih WO2005058359A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10359021 2003-12-15
DE10359021.8 2003-12-15

Publications (2)

Publication Number Publication Date
WO2005058359A2 WO2005058359A2 (fr) 2005-06-30
WO2005058359A3 true WO2005058359A3 (fr) 2005-12-15

Family

ID=34683401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/053496 WO2005058359A2 (fr) 2003-12-15 2004-12-15 Procede de neutralisation des effets de la crp en vue d'augmenter les reactions immunitaires contre le vih

Country Status (1)

Country Link
WO (1) WO2005058359A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105969777A (zh) * 2016-05-11 2016-09-28 南京伯恩立施生物科技有限公司 一种抗人mCRP单链抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000872A1 (fr) * 1989-06-27 1991-01-24 Rush-Presbyterian-St. Luke's Medical Centre Anitcorps monoclonaux contre la proteine reactive c
WO1993010799A1 (fr) * 1991-11-27 1993-06-10 Immtech International Incorporated Procede de traitement d'infections virales
WO2001094951A2 (fr) * 2000-06-08 2001-12-13 Board Of Regents, The University Of Texas System Inhibiteurs d'inflammation induite par la proteine c reactive
US20030171251A1 (en) * 2000-12-18 2003-09-11 Pepys Mark B. Treatment and prevention of tissue damage
WO2004076486A1 (fr) * 2003-02-27 2004-09-10 Theravision Gmbh Methode de diminution des niveaux de proteine c-reactive

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000872A1 (fr) * 1989-06-27 1991-01-24 Rush-Presbyterian-St. Luke's Medical Centre Anitcorps monoclonaux contre la proteine reactive c
WO1993010799A1 (fr) * 1991-11-27 1993-06-10 Immtech International Incorporated Procede de traitement d'infections virales
WO2001094951A2 (fr) * 2000-06-08 2001-12-13 Board Of Regents, The University Of Texas System Inhibiteurs d'inflammation induite par la proteine c reactive
US20030171251A1 (en) * 2000-12-18 2003-09-11 Pepys Mark B. Treatment and prevention of tissue damage
WO2004076486A1 (fr) * 2003-02-27 2004-09-10 Theravision Gmbh Methode de diminution des niveaux de proteine c-reactive

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSS RUSSELL ET AL: "Atherosclerosis is an inflammatory disease", AMERICAN HEART JOURNAL, vol. 138, no. 5 PART 2, November 1999 (1999-11-01), pages S419 - S420, XP009054654, ISSN: 0002-8703 *

Also Published As

Publication number Publication date
WO2005058359A2 (fr) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2002030460A3 (fr) Anticorps therapeutiques
WO2005035584A8 (fr) Anticorps entierement humains agissant contre la 4-1bb humaine (cd137)
WO2004010947A3 (fr) Anticorps humanises contre le 4-1bb humain
EP2298811B8 (fr) Anticorps humains à neutralisation anti-IFN-gamma en tant qu'inhibiteurs sélectifs de chemin IFN-gamma
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2008134724A3 (fr) Procédés d'administration d'anticorps anti-il-5
WO2003016467A3 (fr) Utilisation d'anticorps ayant une forte affinite pour le peptide a$g(b) dans le traitement de pathologies et de maladies liees a a$g(b)
WO2007022520A3 (fr) Renfort induit par anticorps de reponse immune
WO2002032375A3 (fr) Utilisations d'anticorps monoclonal 8h9
WO2005120557A3 (fr) Inhibition du recepteur proteique stimulant les macrophages (ron)
ES2534294T3 (es) Métodos para tratar la preeclampsia
WO2002016401A3 (fr) Anticorps monoclonal ds6 et ses procedes d'utilisation
WO2006072624A3 (fr) Compositions et procedes de traitement d'infections virales
WO2004075850A3 (fr) Immunogene polyvalent
EP1581096A3 (fr) Antigene pipa et anticorps de liaison a celui-ci
WO2003075846A3 (fr) Utilisations d'anticorps 8h9 monoclonaux
WO2003026692A3 (fr) Traitement de l'inflammation articulaire chronique
TW200517124A (en) Fully human antibodies against human 4-1BB
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
WO2004029214A8 (fr) Anticorps lies a la sous-unite alpha de lfa-1 et methodes d'utilisation
WO2002059154A3 (fr) Utilisation de souris transgenique pour isoler efficacement de nouveaux anticorps monoclonaux humains a activite de neutralisation de souches primaires du vih-1 et nouveaux anticorps de neutralisation du vih-1
AU2002341839A1 (en) Monoclonal antibodies to the drug tilmicosin and a method for detecting the same
WO2005058359A3 (fr) Procede de neutralisation des effets de la crp en vue d'augmenter les reactions immunitaires contre le vih
WO2003040341A3 (fr) Anticorps contre le virus de l'hepatite a
WO2005016952A3 (fr) Immunogene polyvalent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase